...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
【24h】

Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.

机译：顺铂，氨甲蝶呤，长春碱和大剂量他莫昔芬的联合化疗治疗移行细胞癌。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We have previously demonstrated that tamoxifen enhanced the chemosensitivity of bladder cancer cells in vitro. In this pilot study, we tested the modulating effect of high-dose tamoxifen to conventional cisplatin, methotrexate, and vinblastine combination chemotherapy (CMV-T) for transitional cell carcinoma (TCC). PATIENTS AND METHODS: Between Nov. 1994 and Mar. 1999, 30 TCC patients were enrolled. Nine patients had muscle-invasive bladder TCC; 21 patients had either unresectable locally advanced diseases or distant metastases. CMV-T consisted of cisplatin 50 mg/m2/day, day 1 & 2; methotrexate 30 mg/m2/day, day 1 & 8; vinblastine 3 mg/m2/day, day 1 & 8; and tamoxifen 200 mg/m2/day, days 1 through 4. RESULTS: A total of 98 courses had been given with an average of 3.27 courses per patient (range: 1-7). Grade III/IV leukopenia and thrombocytopenia occurred in 18% and 21% of total courses, respectively. There were 7 episodes of neutropenic fever, and 3 patients died of sepsis. Non-haematologic toxicities were generally mild. There was no venous thrombosis. Out of 26 patients eligible for evaluation of response, 1 complete and 14 partial responses with an overall response rate of 58% (95% confidence interval: 38-75%) were observed. The mean survival of all patients was 8 months. CONCLUSIONS: The toxicity of CMV-T chemotherapy is moderate, but generally manageable. The response rate of CMV-T for patients with advanced TCC seems to be only comparable to most conventional cisplatin-based combinations. The possible benefit of tamoxifen to enhance chemosensitivity of TCC needs further investigation.
机译：背景：我们以前已经证明他莫昔芬增强了体外膀胱癌细胞的化学敏感性。在这项初步研究中，我们测试了大剂量他莫昔芬对常规顺铂，氨甲蝶呤和长春碱联合化疗（CMV-T）对移行细胞癌（TCC）的调节作用。患者与方法：1994年11月至1999年3月，共有30例TCC患者入组。 9例患者有肌肉浸润性膀胱癌。 21例患有无法切除的局部晚期疾病或远处转移。 CMV-T含顺铂50 mg / m2 /天，第1天和第2天;甲氨蝶呤30 mg / m2 /天，第1和8天;长春碱3 mg / m2 /天，第1和8天;和他莫昔芬200毫克/平方米/天，从第1天到第4天。结果：总共进行了98个疗程，平均每位患者3.27个疗程（范围：1-7）。 III / IV级白细胞减少症和血小板减少症分别占总病程的18％和21％。中性粒细胞减少症发作7次，败血症死亡3例。非血液学毒性一般较轻。没有静脉血栓形成。在有资格评估反应的26例患者中，观察到1例完全缓解和14例部分缓解，总缓解率为58％（95％置信区间：38-75％）。所有患者的平均生存期为8个月。结论：CMV-T化疗的毒性中等，但一般可控。晚期TCC患者的CMV-T应答率似乎仅与大多数传统的基于顺铂的组合相当。他莫昔芬增强TCC的化学敏感性的可能益处有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号